Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omid Hamid

Showing results (51-60 of 188) with videos related to

Pageof 19
Sort By:
Biomarker Research|March 27, 2026
Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patientsHanna Grauers Wiktorin, Viktoria Ekström-Rydén, Ida Ek, et al.
Journal of Translational Medicine|April 22, 2022
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, et al.
Journal of the American Academy of Dermatology|May 20, 2020
Improved survival in women versus men with merkel cell carcinomaMoses Tam, Michael Luu, Christopher A Barker, et al.
Journal of Surgical Oncology|April 17, 2020
The association between facility volume and overall survival in patients with Merkel cell carcinomaEmi J Yoshida, Michael Luu, Morganna Freeman, et al.
American Journal of Clinical Oncology|July 24, 2019
Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-AnalysisChristopher J D Wallis, Raj Satkunasivam, Mohit Butaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaJedd D Wolchok, Axel Hoos, Steven O'Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2020
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 EraMichele Maio, Omid Hamid, James Larkin, et al.
The Oncologist|July 9, 2025
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumorsMartin E Gutierrez, Shou-Ching Tang, John D Powderly, et al.
Cancer Immunity|October 21, 2010
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsJedd D Wolchok, Jeffrey S Weber, Omid Hamid, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2011
An immune-active tumor microenvironment favors clinical response to ipilimumabRui-Ru Ji, Scott D Chasalow, Lisu Wang, et al.
Pageof 19

Showing results (51-60 of 188) with videos related to

Sort By:
Pageof 19
Biomarker Research|March 27, 2026
Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patientsHanna Grauers Wiktorin, Viktoria Ekström-Rydén, Ida Ek, et al.
Journal of Translational Medicine|April 22, 2022
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, et al.
Journal of the American Academy of Dermatology|May 20, 2020
Improved survival in women versus men with merkel cell carcinomaMoses Tam, Michael Luu, Christopher A Barker, et al.
Journal of Surgical Oncology|April 17, 2020
The association between facility volume and overall survival in patients with Merkel cell carcinomaEmi J Yoshida, Michael Luu, Morganna Freeman, et al.
American Journal of Clinical Oncology|July 24, 2019
Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-AnalysisChristopher J D Wallis, Raj Satkunasivam, Mohit Butaney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaJedd D Wolchok, Axel Hoos, Steven O'Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2020
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 EraMichele Maio, Omid Hamid, James Larkin, et al.
The Oncologist|July 9, 2025
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumorsMartin E Gutierrez, Shou-Ching Tang, John D Powderly, et al.
Cancer Immunity|October 21, 2010
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsJedd D Wolchok, Jeffrey S Weber, Omid Hamid, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2011
An immune-active tumor microenvironment favors clinical response to ipilimumabRui-Ru Ji, Scott D Chasalow, Lisu Wang, et al.
Pageof 19